Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;48(10):e912-e915.
doi: 10.1097/CCM.0000000000004502.

Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis

Affiliations
Case Reports

Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis

Brian Trethowan et al. Crit Care Med. 2020 Oct.

Abstract

Objective: Describe a case of post-pneumonectomy vasoplegia managed with angiotensin II. Plasma renin activity was measured at specific time intervals to describe the relationship between endogenous renin activity and exogenous angiotensin II supplementation.

Design: Case report.

Setting: Spectrum Health Cardiothoracic Critical Care Unit.

Patients: Fifty-seven-year-old male.

Interventions: None.

Measurements and main results: Plasma renin activity at five pre-determined time points. Angiotensin II caused a significant increase in mean arterial pressure and a rapid reduction in catecholamine vasopressor doses from 0.75 to 0.31 mcg/kg/min norepinephrine equivalents. Plasma renin activity drawn immediately before angiotensin II initiation was 40 ng/mL/hr (normal, 0.6-3.0 ng/mL/hr) with resultant drop to 22 and 12 ng/mL/hr at 2 and 6 hours after angiotensin II initiation, respectively. The patient suffered no end-organ damage and achieved a positive outcome, discharging home on postoperative day 11.

Conclusion: Exogenous angiotensin II reduced catecholamine vasopressor doses and had an apparent effect in reducing endogenous renin production in this case. Prospective research is warranted to determine the utility of angiotensin II and to better understand it effects on the dysfunctional renin-angiotensin-aldosterone system during vasoplegic shock.

PubMed Disclaimer

References

    1. Levy B, Fritz C, Tacon E, et al. Vasoplegia treatments: The past, the present and the future. CCM Rev 2018; 22:52
    1. Asleh R, Alnsasra H, Daly RC, et al. Predictors and clinical outcomes of vasoplegia in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. J Am Heart Assoc 2019; 8:e013108
    1. Khanna A, English SW, Wang XS, et al.; ATHOS-3 Investigators: Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 377:419–430
    1. Giapreza (Angiotensin II) [Prescribing Information]. 2018San Diego, CA, La Jolla Pharmaceutical Company.
    1. Ostermann M, Boldt D, Harper M, et al. Angiotensin in ECMO patients with refractory shock. Crit Care 2018; 22:228

Publication types

LinkOut - more resources